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ABSTRACT
Nosocomial infections caused by Acinetobacter
baumannii have increased in recent years. Isolates
of multidrug-resistant A. baumannii (MDRAB)
have been recovered in Taiwan since 1999. The
characteristics of 55 patients with MDRAB bac-
teraemia infections occurring between January
2003 and February 2005 were analysed retrospec-
tively. The overall 30-day mortality rate was 49%.
The portal of entry was identiﬁed in 80% of
patients, with the respiratory tract being impli-
cated most frequently. Among the different anti-
microbial regimens prescribed, the combination
of a carbapenem and ampicillin-sulbactam was
associated with a better outcome than the combi-
nation of a carbapenem and amikacin, or a
carbapenem alone.
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Acinetobacter baumannii, an aerobic, Gram-negat-
ive organism, may colonise humans and survive
on dry inanimate objects for prolonged periods
[1–5]. Nosocomial infections caused by A. bau-
mannii have increased in occurrence in recent
years. Clinical manifestations of bloodstream
infections by this organism range from transient
bacteraemia to fulminant disease with high mor-
tality [6]. The emergence of multidrug-resistant
isolates is of great concern worldwide. Known
risk-factors for the development of drug resist-
ance include admission to intensive care units and
previous antibiotic therapy [7]. Most nosocomial
isolates of A. baumannii are now resistant to a
wide range of antibiotics. Carbapenems are the
most common therapeutic choice [8–10], but
resistance to carbapenems has now been reported
in numerous centres [11,12].
Since 1999, isolates of multidrug-resistant
A. baumannii (MDRAB) have been recovered from
patients in Taiwanese hospitals [13–15]. However,
the recorded data were insufﬁcient to compare
the effectiveness of various therapeutic approa-
ches. In the National Taiwan University Hospital,
a carbapenem, alone or in combination with other
antimicrobial agents such as ampicillin-sulbactam
or amikacin, is the treatment used most widely.
The purpose of this retrospective study was to
analyse the response to treatment of MDRAB
bacteraemia.
The investigation was performed at the
National Taiwan University Hospital, a 2200-bed
tertiary care centre. All cases of MDRAB bacter-
aemia treated between January 2003 and February
2005 were analysed retrospectively. Blood cul-
tures were processed using the BACTEC 9240
blood culture system (Becton Dickinson, Sparks,
MD, USA). Antimicrobial susceptibilities were
determined by the CLSI (formerly NCCLS) disk-
diffusion method [16]. MDRAB was deﬁned in
this study as an A. baumannii isolate resistant
to ceftazidime, cefepime, ticarcillin-clavulanate,
piperacillin-tazobactam, aztreonam, imipenem,
meropenem, gentamicin, amikacin, oﬂoxacin
and ciproﬂoxacin by the routine disk-diffusion
method. The portal of entry of MDRAB was
identiﬁed according to clinical evidence. Multiple
logistic regression analysis with stepwise selec-
tion was used to determine the factors inﬂuencing
mortality.
The characteristics of 55 patients with
MDRAB bacteraemia are listed in Table 1.
Antimicrobial treatment regimens before the epi-
sode of MDRAB bacteraemia varied, with carbap-
enems and ﬂuoroquinolones being the two agents
used most commonly. The most common portal of
entry was the respiratory tract. In patients with
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polymicrobial bacteraemia, the concomitant
pathogens identiﬁed most commonly were
enterococci, Klebsiella pneumoniae, Enterobacter cloa-
cae, Staphylococcus epidermidis and Pseudomonas
aeruginosa.
The agents used most frequently for the treat-
ment of MDRAB bacteraemia were carbapenems,
amikacin and ampicillin-sulbactam, either as mo-
notherapy or in combination. A carbapenem was
prescribed for 38 patients, ampicillin-sulbactam
for 31 patients, and amikacin for 18 patients.
Forty-six of the 55 patients were treated with a
combination of two or more of the above antibi-
otics. Eleven patients had profound septic shock
and died within 3 days of the onset of bacterae-
mia. One hospice patient died without receiving
antimicrobial treatment. After data for these
patients had been excluded from the analysis,
the median period of therapy was 16.5 days for a
carbapenem, 17 days for ampicillin-sulbactam,
and 12 days for amikacin. Twenty-seven (63%)
patients showed a good clinical response, 12
(28%) failed to respond, and no clear data were
available for four (9%) patients.
Overall, 32 patients died during hospitalisation,
giving a crude mortality rate of 58%. The median
interval from infection to death was 9 days.
Mortality occurred within 30 days of the onset
of bacteraemia for 27 (49%) patients. Septic shock
was the only independent predictor of mortality
(OR 8.48) in the multiple logistic regression
analysis.
Among the different antimicrobial regimens,
the combination of a carbapenem and ampicillin-
sulbactam (n = 26 patients, mortality rate 30.8%)
for the treatment of MDRAB bacteraemia was
associated with a better outcome than the combi-
nation of a carbapenem and amikacin (n = 10
patients, mortality rate 50.0%) or a carbapenem
alone (n = 12 patients, mortality rate 58.3%)
(Fig. 1). No data were available concerning sus-
ceptibility to tigecycline, doxycycline, rifampicin
or colistin.
A previous study showed that bacteraemia
following initial respiratory tract, intravascular
catheter and wound infections was the most
signiﬁcant infection caused by A. baumannii [17].
In the present study, pneumonia and urinary
tract infection were associated with > 70% of
cases of MDRAB bacteraemia. The in-hospital
mortality rate of MDRAB bacteraemia in the
present study was similar to that reported in a
previous series carried out between 1999 and
2002 [14]. A survival beneﬁt was demonstrated
for patients who received a combination of a
carbapenem and ampicillin-sulbactam. Sulbac-
tam has in-vitro activity against A. baumannii,
and the survival beneﬁt may be a consequence
of the synergic activity of a carbapenem and
sulbactam against MDRAB [9,18], perhaps
Table 1. Characteristics of patients with multidrug-resist-
ant Acinetobacter baumannii (MDRAB) bacteraemia
Characteristic
Total (n = 55)
n (range or %)
Male, n (%) 34 (62%)
Age, median years (range) 62 (0)93)
Hospitalisation before MDRAB bacteraemia,
median days (range)
34 (4)237)
Treatment setting, n (%)
Intensive care unit 45 (82%)
Ordinary ward 10 (18%)
Clinical manifestations, n (%)
Fever 46 (85%)
Septic shock 22 (41%)
Acute respiratory distress syndrome ⁄ acute lung injury 22 (40%)
Previous antibiotic use for > 3 days, n (%)
Carbapenem 17 (31%)
Fluoroquinolone 16 (29%)
Third-generation cephalosporin 5 (9%)
Fourth-generation cephalosporin 5 (9%)
Piperacillin-tazobactam, ticarcillin-clavulanate 3 (5%)
Aztreonam 1 (2%)
None 11 (20%)
Polymicrobial bacteraemia, n (%) 20 (36%)
Portal(s) of entry (may be multiple), n (%)
Unknown 11 (20%)
Respiratory tract 33 (60%)
Intravenous catheter 12 (22%)
Urinary tract 2 (4%)
Wound 1 (2%)
Central nervous system (post-surgery) 1 (2%)
In-hospital mortality, n (%) 32 (58%)
30-day mortality, n (%) 27 (49%)
Hospitalisation after MDRAB bacteraemia,
median days (range)
24.5 (0)136)
Fig. 1. Mortality with different antimicrobial regimens for
55 patients with multidrug-resistant Acinetobacter bauman-
nii bacteraemia.
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resulting from differences in binding to bacterial
penicillin-binding proteins [9]. A limitation of
this study was that no comparison of the
activity of different antibiotics according to
sulbactam susceptibility was made. A previous
study showed that ampicillin-sulbactam in com-
bination with amikacin had a synergic or partial
synergic effect against MDRAB [19], but patients
treated with ampicillin-sulbactam and amikacin
in the present study did not have improved
survival rates (data not shown). Although both
sulbactam and ampicillin-sulbactam are avail-
able commercially in Taiwan, only the latter is
available at our hospital.
Another potential antimicrobial agent for the
treatment of MDRAB infection is colistin. Colistin
was used during the 1960s, but was abandoned
because of nephrotoxicity and neurotoxicity [20].
Levin et al. [21] reported a good outcome follow-
ing the treatment of MDRAB infection with
intravenous colistin; thus, colistin, either alone
or in combination with rifampicin, might be a
viable alternative for the treatment of MDRAB
bacteraemia [20]. A prospective trial with detailed
antimicrobial susceptibility tests is needed to
provide more evidence for the selection of opti-
mal antimicrobial therapy for MDRAB infection.
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